BACKGROUND AND PURPOSE: Hypertension is associated with gut dysbiosis. Here we have evaluated the effects of the angiotensin receptor antagonist losartan on gut microbiota in spontaneously hypertensive rats (SHR) to assess their contribution to its antihypertensive effects. EXPERIMENTAL APPROACH: Twenty-week-old Wistar Kyoto rats (WKY) and SHR were treated with losartan for 5 weeks (SHR-losartan). Faecal microbiota transplantation (FMT) was performed from donor SHR-losartan group to recipient untreated-SHR. Blood pressure (BP) was measured using tail-cuff plethysmography. Composition of the gut microbiota was assessed by amplification of the V3-V4 region of 16S rRNA gene. T cells were analysed in gut/aorta by flow cytometry. KEY RESULTS: Faeces from SHR showed gut dysbiosis, characterised by higher Firmicutes/Bacteroidetes ratios, lower acetate- and higher lactate-producing bacteria, and lower levels of strict anaerobic bacteria, effects which were restored to normal by losartan. Improvement of gut dysbiosis was linked to higher colonic integrity and lower sympathetic drive in the gut. In contrast, hydralazine reduced BP, but it neither restored gut dysbiosis nor colonic integrity. FMT from SHR-losartan to SHR reduced BP, improved the aortic endothelium-dependent relaxation to ACh, and reduced NADPH oxidase activity. These vascular changes were accompanied by both increased Treg and decreased Th17 cell populations in the vascular wall. CONCLUSION AND IMPLICATIONS: In SHR, losartan treatment reduced gut dysbiosis and sympathetic drive in the gut, thus improving gut integrity. The changes induced by losartan in gut microbiota contributed, in part, to protecting the vasculature and reducing BP, possibly by modulating the immune system in the gut.
BACKGROUND AND PURPOSE:Hypertension is associated with gut dysbiosis. Here we have evaluated the effects of the angiotensin receptor antagonist losartan on gut microbiota in spontaneously hypertensiverats (SHR) to assess their contribution to its antihypertensive effects. EXPERIMENTAL APPROACH: Twenty-week-old Wistar Kyoto rats (WKY) and SHR were treated with losartan for 5 weeks (SHR-losartan). Faecal microbiota transplantation (FMT) was performed from donor SHR-losartan group to recipient untreated-SHR. Blood pressure (BP) was measured using tail-cuff plethysmography. Composition of the gut microbiota was assessed by amplification of the V3-V4 region of 16S rRNA gene. T cells were analysed in gut/aorta by flow cytometry. KEY RESULTS: Faeces from SHR showed gut dysbiosis, characterised by higher Firmicutes/Bacteroidetes ratios, lower acetate- and higher lactate-producing bacteria, and lower levels of strict anaerobic bacteria, effects which were restored to normal by losartan. Improvement of gut dysbiosis was linked to higher colonic integrity and lower sympathetic drive in the gut. In contrast, hydralazine reduced BP, but it neither restored gut dysbiosis nor colonic integrity. FMT from SHR-losartan to SHR reduced BP, improved the aortic endothelium-dependent relaxation to ACh, and reduced NADPH oxidase activity. These vascular changes were accompanied by both increased Treg and decreased Th17 cell populations in the vascular wall. CONCLUSION AND IMPLICATIONS: In SHR, losartan treatment reduced gut dysbiosis and sympathetic drive in the gut, thus improving gut integrity. The changes induced by losartan in gut microbiota contributed, in part, to protecting the vasculature and reducing BP, possibly by modulating the immune system in the gut.
Authors: Tlili Barhoumi; Daniel A Kasal; Melissa W Li; Layla Shbat; Pascal Laurant; Mario F Neves; Pierre Paradis; Ernesto L Schiffrin Journal: Hypertension Date: 2011-01-24 Impact factor: 10.190
Authors: Stephen P H Alexander; Arthur Christopoulos; Anthony P Davenport; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2019-12 Impact factor: 8.739
Authors: Stephen P H Alexander; Doriano Fabbro; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2019-12 Impact factor: 8.739
Authors: Julia König; Jerry Wells; Patrice D Cani; Clara L García-Ródenas; Tom MacDonald; Annick Mercenier; Jacqueline Whyte; Freddy Troost; Robert-Jan Brummer Journal: Clin Transl Gastroenterol Date: 2016-10-20 Impact factor: 4.488
Authors: Nicola Wilck; Mariana G Matus; Sean M Kearney; Scott W Olesen; Kristoffer Forslund; Hendrik Bartolomaeus; Stefanie Haase; Anja Mähler; András Balogh; Lajos Markó; Olga Vvedenskaya; Friedrich H Kleiner; Dmitry Tsvetkov; Lars Klug; Paul I Costea; Shinichi Sunagawa; Lisa Maier; Natalia Rakova; Valentin Schatz; Patrick Neubert; Christian Frätzer; Alexander Krannich; Maik Gollasch; Diana A Grohme; Beatriz F Côrte-Real; Roman G Gerlach; Marijana Basic; Athanasios Typas; Chuan Wu; Jens M Titze; Jonathan Jantsch; Michael Boschmann; Ralf Dechend; Markus Kleinewietfeld; Stefan Kempa; Peer Bork; Ralf A Linker; Eric J Alm; Dominik N Müller Journal: Nature Date: 2017-11-15 Impact factor: 49.962
Authors: Sepiso K Masenga; Benson Hamooya; Joy Hangoma; Valerie Hayumbu; Lale A Ertuglu; Jeanne Ishimwe; Sharla Rahman; Mohammad Saleem; Cheryl L Laffer; Fernando Elijovich; Annet Kirabo Journal: J Hum Hypertens Date: 2022-04-25 Impact factor: 3.012
Authors: Iñaki Robles-Vera; Marta Toral; Néstor de la Visitación; Manuel Sánchez; Manuel Gómez-Guzmán; Raquel Muñoz; Francesca Algieri; Teresa Vezza; Rosario Jiménez; Julio Gálvez; Miguel Romero; Juan Miguel Redondo; Juan Duarte Journal: Br J Pharmacol Date: 2020-02-03 Impact factor: 8.739
Authors: Pablo Méndez-Albiñana; Ángel Martínez-González; Laura Camacho-Rodríguez; Álvaro Ferreira-Lazarte; Mar Villamiel; Raquel Rodrigues-Díez; Gloria Balfagón; Ana B García-Redondo; Mª Isabel Prieto-Nieto; Javier Blanco-Rivero Journal: Antioxidants (Basel) Date: 2022-03-30
Authors: Adrián Cortés-Martín; Carlos E Iglesias-Aguirre; Amparo Meoro; María Victoria Selma; Juan Carlos Espín Journal: Microorganisms Date: 2020-03-15